Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of Kytril® from F.Hoffmann-La Roche Limited (“Roche”).
Kytril® (granisetron hydrochloride) is an injectable and oral treatment for nausea and vomiting caused by other medical treatments, such as chemotherapy or radiotherapy. It is the third acquisition by Atnahs from Roche following Naprosyn®/ Anaprox® and Toradol® in 2015.
Amit Patel, Atnahs’ Managing Director, comments,
“The acquisition of Kytril® expands our global presence to over 100 territories worldwide and give us a significant presence in the Middle East and Latin America in particular. Following this acquisition, we will have an infrastructure capable of assimilating a wide range of products or bundle of products globally.”
Tony Playle, Atnahs’ Strategy Director, further comments,
“We are delighted to continue to grow our relationship with Roche. Our team is now focused once again on working in partnership with Roche on transitioning the product seamlessly into our international distribution network.”
Atnahs is a family-owned specialty pharmaceutical business, focussed upon acquiring mature branded medicines out of large cap and specialty pharma and developing its own niche generic medicines. Atnahs has now completed seven major acquisitions since its inception in 2013, and currently operates a portfolio of over 10 key medicines across more than 50 territories.